Jaguar Health Announces Time Change for March 27th Investor Webcast to 8:00 AM EDT
Jaguar Health, Inc. (NASDAQ:JAGX) has announced a change in the timing of its investor webcast, now scheduled for March 27, 2023 at 8:00 AM EDT, to discuss the fourth-quarter 2022 financial results and corporate updates. The company plans to file its Annual Report on March 24, 2023, for the fiscal year ended December 31, 2022. Jaguar focuses on developing plant-based prescription medications for gastrointestinal distress in humans and animals. Its subsidiary, Napo Pharmaceuticals, is conducting a pivotal Phase 3 trial for the drug crofelemer aimed at cancer patients experiencing diarrhea.
- Scheduled investor webcast to discuss Q4 2022 financials, indicating proactive communication with investors.
- Filing of Annual Report on March 24, 2023, showing compliance and transparency in financial reporting.
- Focus on developing plant-based medications, aligning with sustainable health trends.
- No significant financial metrics disclosed in the press release, limiting insights into performance.
Click here to register for webcast
Company plans to file its Annual Report on March 24, 2023 on Form 10-K for the fiscal year ended December 31, 2022
SAN FRANCISCO, CA / ACCESSWIRE / March 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company investor webcast scheduled for Monday, March 27, 2023 to review fourth-quarter 2022 financials and provide corporate updates will now take place at 8:00 a.m. Eastern Daylight Time instead of 8:30 a.m.
Participation Instructions for Webcast
When: Monday, March 27, 2023 at 8:00 AM Eastern Daylight Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics & Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar Health will hold an investor webcast on March 27, 2023, and the expectation that Jaguar Health will file its Annual Report on March 24, 2023 for the fiscal year ended December 31, 2022. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/745692/Jaguar-Health-Announces-Time-Change-for-March-27th-Investor-Webcast-to-800-AM-EDT
FAQ
When is Jaguar Health's investor webcast scheduled?
What will Jaguar Health discuss in the upcoming webcast?
When will Jaguar Health file its Annual Report?
What is the focus of Jaguar Health's business operations?
What is the current status of Jaguar Health’s drug candidate crofelemer?
